New PET tracer lights up pancreatic tumors in early trial
NCT ID NCT06129422
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 22 times
Summary
This early-phase study tested a new imaging agent called NMK89 in 10 people with pancreatic cancer that produces a specific protein (MUC5AC). The agent was given as a single infusion and then tracked with PET/CT scans to see where it goes in the body and how safe it is. The goal was not to treat the cancer, but to improve detection and understanding of the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
BAMF Health
Grand Rapids, Michigan, 49503, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.